A clinical and immunological study of a myasthenia gravis patient treated with infliximab

Acta Neurol Scand. 2007 Apr;115(4):279-83. doi: 10.1111/j.1600-0404.2006.00778.x.


Objectives: To measure clinical and immunological parameters in a patient with myasthenia gravis (MG) treated with antibodies against tumour necrosis factor-alpha (infliximab, Remicade).

Patient and methods: A patient with severe MG received repeated injections of infliximab. His muscle function score was monitored and the immunological parameters were followed using enzyme-linked immunosorbent assay, flow cytometry and radioimmunoassay.

Results: The patient improved in muscle fatigability tests and the levels of antibodies against the acetylcholine receptor decreased during treatment. The activation marker human leucocyte antigen-DR on CD4(+) T cells also decreased.

Conclusion: Treatment with infliximab might be beneficial for patients with severe MG but demands careful monitoring of possible serious side-effects.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Humans
  • Immunologic Factors / therapeutic use*
  • Infliximab
  • Male
  • Middle Aged
  • Muscle Strength / physiology
  • Myasthenia Gravis / drug therapy
  • Myasthenia Gravis / immunology*
  • Myasthenia Gravis / physiopathology*
  • Recovery of Function / physiology
  • Treatment Outcome


  • Antibodies, Monoclonal
  • Immunologic Factors
  • Infliximab